60 Degrees PharmaceuticalsSXTP
SXTP
About: 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Employees: 2
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.19% less ownership
Funds ownership: 2.96% [Q2] → 1.77% (-1.19%) [Q3]
30% less funds holding
Funds holding: 10 [Q2] → 7 (-3) [Q3]
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
54% less capital invested
Capital invested by funds: $90.1K [Q2] → $41.4K (-$48.7K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for SXTP.
Financial journalist opinion
Based on 3 articles about SXTP published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,021,549 shares of its common stock at a purchase price of $1.021 per share. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to an aggregate of 2,043,098 shares of common stock.
Neutral
GlobeNewsWire
1 week ago
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. Enrollment expected to commence Q3 2025.
Neutral
GlobeNewsWire
3 weeks ago
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
Neutral
GlobeNewsWire
1 month ago
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
Neutral
GlobeNewsWire
1 month ago
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D.
Neutral
Accesswire
2 months ago
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m.
Negative
Zacks Investment Research
2 months ago
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $3.60 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
Neutral
GlobeNewsWire
4 months ago
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile.
Positive
Benzinga
4 months ago
Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying
The Dow Jones index closed higher by more than 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
Charts implemented using Lightweight Charts™